Pfizer Inc. (PFE)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Do Nothing: input snapshot price 26.80 exceeds the strategy's $25.00 ceiling.
Company overview
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Fundamental
fairPfizer's stable income and margins are offset by negative growth trends and regulatory risks.
Balanced fundamentals: strong gross margins and solid cash generation, but elevated leverage and negative multi-year growth after the COVID product wind-down. Recent quarters show GAAP volatility from impairments/restructuring, so cash-flow-based valuation looks better than headline P/E; insiders have recently bought shares near current levels.
Sentiment
fairSentiment is mixed, with recent FDA approval countered by negative trial news.
Recent headlines are dominated by announced Q2 results (beat + low-end revenue guidance lift and added cost-cutting) and an announced positive Phase 3 vitiligo readout for LITFULO, leaving last ~14d media tone slightly positive versus a neutral 30–90d baseline. Offsetting trade-press coverage of pipeline pruning (including an obesity-asset exit) keeps the near-term picture two-sided; moderate red-flag cap applied for conflicting actionable signals.
Technical
goodTechnical indicators show a strong downtrend with no confirmed bullish setup.
Technical score 4/5: the chart is strong, with price above SMA20/50/200 and EMA9/21, MACD positive above signal, RSI14 at 65.00, and ADX14 at 63.85 confirming trend strength. The main chart blemish is short-term extension after a fast two-week advance.
You’re looking at 2026-08-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

